

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

**VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSED IN PHASE III CLINICAL STUDY OF KN026
FOR ADJUVANT TREATMENT OF HER2+ BC**

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the first patient has been successfully dosed in a phase III clinical study of KN026, co-developed with Shanghai JMT-Bio Technology Co., Ltd. (上海津曼特生物科技有限公司), a subsidiary of CSPC Pharmaceutical Group Limited (Stock Code: 1093), in combination with the docetaxel (albumin-bound) for injection (HB1801) and chemotherapy as adjuvant treatment for human epidermal growth factor receptor 2 (“**HER2**”)-positive (“**HER2+**”) breast cancer (“**BC**”) (study code: KN026-007).

BC is the most prevalent malignant tumor among women in the PRC, with the HER2+ subtype accounting for approximately 20% to 30% of all cases. Although trastuzumab, with or without pertuzumab, in combination with chemotherapy has significantly reduced the risk of recurrence, subgroup analyses from multiple clinical studies indicate that patients with HER2+ BC who are lymph node-positive, particularly those with four or more positive lymph nodes, continue to face a high risk of recurrence. Compared with regimens containing trastuzumab alone, dual-targeted therapy in combination with chemotherapy as adjuvant treatment for HER2+ BC can further reduce the risk of recurrence, with the most pronounced benefit observed in lymph node-positive patients. Accordingly, the exploration of more effective adjuvant treatment strategies to improve long-term outcomes for this patient population is of significant clinical importance.

KN026-007 is a randomized, controlled, open-label, multicenter phase III clinical study, which is expected to enroll approximately 1,800 patients with resectable HER2+ BC who have histologically confirmed involvement of four or more regional lymph nodes following surgery. Eligible patients will be randomized on a 1:1 basis to compare the efficacy and safety of KN026 in combination with HB1801 and chemotherapy versus trastuzumab plus pertuzumab in combination with chemotherapy as adjuvant treatment. The primary endpoint of the study is investigator-assessed invasive disease-free survival (iDFS). Secondary endpoints include disease-free survival (DFS), recurrence-free interval (RFI), distant recurrence-free interval (DRFI), overall survival (OS), safety, pharmacokinetics and immunogenicity.

ABOUT KN026 (Anbenitamab, 安尼妥單抗)

KN026 was designed to be a global-level next-generation HER2-targeted therapy. With its innovative structure, it binds simultaneously to 2 distinct clinically validated epitopes of HER2 (paratope II and IV), and maintains a wild type Fc region. This results in (i) a dual blockade of HER2-related signaling pathways, (ii) strengthened binding to HER2 receptors, (iii) a reduction of HER2 proteins on the cell surface, and (iv) increased tumor killing effect through intact antibody dependent cell-mediated cytotoxicity. These binding mechanisms enable KN026 to have excellent tumor suppressive effect. In August 2021, we cooperated with Shanghai JMT-Bio Technology Co., Ltd. and entered into a licensing agreement to develop and commercialize KN026 for the treatment of BC and gastric cancer (“GC”) in Mainland China.

KN026 has been granted Breakthrough Therapy Designation by the National Medical Products Administration (國家藥品監督管理局) (the “NMPA”) as second-line or above treatment of HER2+ GC/gastroesophageal junction cancer. Furthermore, the New Drug Application for KN026 in combination with chemotherapy for this indication was accepted by the NMPA in September 2025. It has also been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HER2+ or HER2-low GC.

Currently, multiple phase III clinical trials are undergoing in the PRC, including KN026 in combination with albumin-bound docetaxel in the first-line treatment for HER2+ BC and KN026 in combination with albumin-bound docetaxel as neoadjuvant therapy of BC.

ABOUT Docetaxel (Albumin-Bound)

Docetaxel (Albumin-Bound) for Injection (HB1801) is a product developed by CSPC Pharmaceutical Group Limited using innovative technology to encapsulate docetaxel in human serum albumin. Compared with conventional docetaxel injection, this novel formulation offers several advantages: (1) Safety: No premedication with corticosteroids is required, and it enables high-concentration and rapid administration, thereby improving safety and patient compliance. (2) Efficacy: It demonstrates potent anti-tumor activity in multiple preclinical tumor models and allows higher clinical dosing to further improve therapeutic effects.

Data from multiple clinical trials have consistently showed that HB1801 exhibited favorable efficacy and safety profiles, achieving the goal of reduced toxicity and enhanced efficacy. Several phase III trials of HB1801 in patients with BC and GC are ongoing.

ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in the PRC with a fully integrated proprietary technology platform in antibody-drug conjugates (“ADC(s)”), bispecific antibodies and multi-functional protein engineering. The Company’s highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology, including, among others, one product approved for marketing by the NMPA and multiple products in phase III or pivotal clinical trial stages. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop and/or ultimately market KN026 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, March 24, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.